Learn About Ewing Sarcoma
Ewing sarcoma is a cancerous tumor that occurs in bones or soft tissues, such as cartilage or nerves. There are several types of Ewing sarcoma, including Ewing sarcoma of bone, extraosseous Ewing sarcoma, peripheral primitive neuroectodermal tumor (pPNET), and Askin tumor. These tumors are considered to be related because they have similar genetic causes. These types of Ewing sarcoma can be distinguished from one another by the tissue in which the tumor develops. Approximately 87 percent of Ewing sarcomas are Ewing sarcoma of bone, which is a bone tumor that usually occurs in the thigh bones (femurs), pelvis, ribs, or shoulder blades. Extraosseous (or extraskeletal) Ewing sarcoma describes tumors in the soft tissues around bones, such as cartilage. pPNETs occur in nerve tissue and can be found in many parts of the body. A type of pPNET found in the chest is called Askin tumor.
The most common mutation that causes Ewing sarcoma involves two genes, the EWSR1 gene on chromosome 22 and the FLI1 gene on chromosome 11. A rearrangement (translocation) of genetic material between chromosomes 22 and 11, written as t(11;22), fuses part of the EWSR1 gene with part of the FLI1 gene, creating the EWSR1/FLI1 fusion gene. This mutation is acquired during a person's lifetime and is present only in tumor cells. This type of genetic change, called a somatic mutation, is not inherited.
Approximately 3 per 1 million children each year are diagnosed with a Ewing sarcoma. It is estimated that, in the United States, 250 children are diagnosed with one of these types of tumor each year. Ewing sarcoma accounts for about 1.5 percent of all childhood cancers, and it is the second most common type of bone tumor in children (the most common type of bone cancer is called osteosarcoma).
This condition is generally not inherited but arises from a mutation in the body's cells that occurs after conception. This alteration is called a somatic mutation.
Cleveland Clinic Children's Outpatient Center
Peter Anderson is a Pediatrics provider in Cleveland, Ohio. Dr. Anderson has been practicing medicine for over 51 years and is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Osteosarcoma, Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, and Adult Soft Tissue Sarcoma.
The Children's Hospital At Montefiore
David Loeb, MD, PhD, is Chief, Pediatric Hematology, Oncology and Cellular Therapy at Children’s Hospital at Montefiore and Professor, Pediatrics and Professor, Developmental and Molecular Biology at Montefiore Einstein. His clinical work focuses on tumors of connective tissue, such as bone and muscle. He also has expertise in the care of children with other solid tumors. As a member of the bone marrow transplantation team, Dr. Loeb also cares for patients with acute leukemias and has expertise in the application of immunotherapy to childhood cancer. Dr. Loeb is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, and Bone Tumor.
Johns Hopkins All Children's Outpatient Care, St. Petersburg
Dr. Metts specializes in pediatric hematology/oncology in the Johns Hopkins All Children's Cancer & Blood Disorders Institute. He sees patients on our main campus in St. Petersburg and at the Johns Hopkins All Children’s Outpatient Care Center in Tampa. He joined the hospital in 2016. He received his medical degree from the University of South Carolina School of Medicine and completed an internship and residency in pediatrics at Johns Hopkins All Children’s Hospital through the University of South Florida Morsani School of Medicine. Dr. Metts then trained at Emory University School of Medicine as a pediatric hematology/oncology fellow. His clinical interests include sarcomas, rare solid tumors, and Phase 1 and Phase 2 trials for pediatric solid tumors. Dr. Metts is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, and Adult Soft Tissue Sarcoma.
Summary: The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will test 2 combinations of therapy and participants will be randomly assigned to either Arm A or Arm B. The purpose of the phase I study is to determine the highest ...
Summary: RAD3CAR is a phase I study designed to evaluatethe safety of B7-H3-CAR T cells and lymphodepletion in combination with hypofractionated radiation therapy. Primary objective: \- To evaluate the safety of B7-H3-CAR T cell therapy after priming with hypofractionated radiation therapy (HFRT) and lymphodepleting chemotherapy in patients ≤ 21 years of age with relapsed/refractory B7-H3+ sarcomas. Second...
Published Date: June 01, 2016
Published By: National Institutes of Health